Intellia Therapeutics
NTLA
130 hedge funds and large institutions have $557M invested in Intellia Therapeutics in 2018 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 44 increasing their positions, 27 reducing their positions, and 18 closing their positions.
106% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 18
63% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 27
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
19% more capital invested
Capital invested by funds: $467M → $557M (+$89.9M)
16% more funds holding
Funds holding: 112 → 130 (+18)
5.04% less ownership
Funds ownership: 67.35% → 62.31% (-5%)
57% less call options, than puts
Call options by funds: $4M | Put options by funds: $9.36M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$54.8M |
| 2 |
Morgan Stanley
New York
|
+$38.9M |
| 3 |
Chevy Chase Trust
Bethesda,
Maryland
|
+$14.5M |
| 4 |
State Street
Boston,
Massachusetts
|
+$9.51M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$7.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AVAI
Atlas Venture Associates IX
Boston,
Massachusetts
|
-$32M |
| 2 |
O
OrbiMed
New York
|
-$30.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$13.2M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$12.1M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$7.66M |
NTLA Hedge Fund Activity: Q1 2018 in Review
130 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q1 2018, worth a combined $557M — up 19% from $467M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new NTLA positions and 18 closed out — a net gain of 19 holders — while 44 added to existing stakes and 27 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $54.8M. The largest seller was Atlas Venture Associates IX, cutting an estimated $32M.
- 130 institutional investors held Intellia Therapeutics (NTLA) as of Q1 2018, up from 112 in Q4 2017.
- Funds reported $557M of Intellia Therapeutics stock for Q1 2018, up 19% quarter-over-quarter.
- 37 funds opened new Intellia Therapeutics positions in Q1 2018 and 18 closed out, a net change of +19 holders.
- The largest Intellia Therapeutics buyer in Q1 2018 was ARK Investment Management, an estimated $54.8M added.
- The largest Intellia Therapeutics seller in Q1 2018 was Atlas Venture Associates IX, an estimated $32M sold.
Based on aggregated 13F filings for Q1 2018.